N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia

Pharmacotherapy

Volumn 17, Issue 6, 1997, Pages 1300-1304

  Combs, Michael D ^a   Perry, Paul J ^a,b   Bever, Kristine A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CLOZAPINE DERIVATIVE; DRUG METABOLITE; MARKER; NORCLOZAPINE;

ADULT; AGRANULOCYTOSIS; ARTICLE; DRUG BLOOD LEVEL; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING;

ADOLESCENT; ADULT; AGING; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX CHARACTERISTICS; SMOKING;

EID: 0030666770     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
2. Claghorn J, Honigfeld G, Abuzzahab F, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987:7:377-84.
3. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine-a study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241-8.
4. Alvir JMJ, Leiberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis-incidence and risk factors in the United States. N Engl J Med 1993;329:162-7.
5. Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsychotics. Drug Saf 1993;9:429-36.
6. Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatric Services 1996;47:2-56.
7. Safferman AZ, Lieberman JA, Alvir JMJ, Howard A. Rechallenge in clozapine-associated agranulocytosis [letter]. Lancet 1992;339:1296-7.
8. Pfister GM, Hanson DR, Roerig JL, Landbloom R, Popkin MK. Clozapine-induced agranulocytosis in a Native American: HLA typing and further support for an immune-mediated mechanism. J Clin Psychiatry 1992;53:242-4.
9. Murphy MF, Riordan T, Minchinton RM, et al. Demonstration of an immune-mediated mechanism of penicillin-induced neutropenia and thrombocytopenia. Br J Haematol 1983;55:155-60.
10. Pisciotta AV, Cronkite C. Aprindine-induced agranulocytosis, evidence for immunologic mechanism. Arch Intern Med 1983;143:241-3.
11. Weitzman SA, Stossel TP. Drug-induced immunological neutropenia. Lancet 1978:1:1068-71.
12. Smith CS, Chinn S, Watts RW. The sensitivity of human bone marrow granulocyte/monocyte precursor cells to phenylbutazone, oxyphenbutazone and gamma-hydroxyphenylbutazone in vitro, with observations on the bone marrow colony formation in phenylbutazone-induced granulocytopenia. Biochem Pharmacol 1977:26:847-52.
13. Jimenez JJ, Arimura GK, Abou-Khalil WH, Isildar M, Yunis AA. Chloramphenicol-induced bone marrow injury: possible role of bacterial metabolites of chloramphenicol. Blood 1987;70:1180-5.
14. Gualde N, Malinvaud G. In vitro generation of cytotoxic lymphocytes during noramidopyrine-induced agranulocytosis. Clin lmmunol lmmunopathol 1982;24:220-6.
15. Fischer V, Haar JA, Greiner L, Lloyd RV, Mason RP. Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis. Mol Pharmacol 1991;40:846-53.
16. Mason RP, Fischer V. Possible role of free radical formation in drug-induced agranulocytosis. Drug Saf 1992;7(S1):45-50.
17. Gerson SL, Arce C, Meltzer HY. N-Desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994;86:555-61.
18. Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992;7(Sl):17-25.
19. Hasegawa M, Cola PA, Meltzer HY. Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology 1994;11:45-7.
20. Centorrino F, Baldessarini RJ, Flood JG, Kando JC, Frankenburg FR. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry 1995;152:610-12.
21. Alvir JMA, Lieberman JA. A reevaluation of the clinical characteristics of clozapine-induced granulocytosis in light of the United States experience. J Clin Psychiatry 1994;55(suppl B):87-9.
22. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994;14:119-25.
23. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology 1989;99:S38-40.
24. Lovdahl MJ, Perry PJ, Miller DD. The assay of clozapine and n-desmethylclozapine in human plasma by high-performance liquid chromatography. Ther Drug Monit 1991:13:69-72.